New KOL solution – based upon newly acquired Qforma CrowdLink
business – to help life sciences companies drive more successful product
launches
PLEASANTON, Calif. & MORRISTOWN, N.J.--(BUSINESS WIRE)--
Veeva Systems (NYSE: VEEV) kicked off the ExL Pharma Medical Affairs
Strategic Summit today unveiling Veeva
KOL Data & Services, a new solution empowering life sciences
companies to better understand and engage stakeholders worldwide. It
delivers in-depth profiles of all relevant key opinion leaders (KOLs)
and targeted engagement plans for more successful product launches.
Veeva’s KOL solution builds on the recently acquired Qforma CrowdLink
KOL database, and leading segmentation and network visualization
capabilities, providing the most sophisticated solution on the market
today. The Qforma Crowdlink team, now part of Veeva, brings specialized
expertise in KOL data, analysis, and engagement planning.
Two thirds of all pharmaceutical product launches today do not meet
sales forecasts1 – a concern largely attributed to global
market access restrictions, intensifying regulatory pressure, and a
rapidly changing provider landscape. Building trusted relationships with
all relevant stakeholders is critical to a successful launch. Veeva KOL
Data & Services provides the insights needed to identify and nurture the
most important relationships.
Veeva KOL Data & Services allows launch teams to accurately identify the
right KOLs around the world and maximize coverage. It also delivers
in-depth KOL profiles to personalize all interactions. Interactive
relationship maps and hundreds of segmentation overlays, coupled with
expert services, help to develop highly targeted engagement plans in
each therapeutic area. All data is meticulously validated by specialized
researchers around the globe to ensure ongoing completeness and accuracy.
New Veeva KOL Data & Services
It’s global – worldwide coverage, consistent view of KOLs
globally, yet tailored to each local market’s needs.
It’s robust – provides accurate and compliant data about people,
institutions, activities, relationships and sentiment.
It’s actionable – Targeted engagement plans created for you.
Further explore with easy segmentation and dynamic visualization of KOL
networks.
Kilian Weiss
, founder of Mederi AG and former Qforma CEO, joins Veeva as
general manager of KOL Solutions with the acquisition of Qforma’s
Crowdlink KOL business. He brings more than a decade of leadership in
KOL data and services. “Clearly, communicating value to patients,
providers, and payers is critical to a successful launch,” said Weiss.
“We are dedicated to helping the industry bring products to market with
the most robust KOL data and advisory services, on a global scale.”
The Veeva KOL Data & Services solution, proven in more than 70
countries, provides consistent data quality, compliance standards, and
planning processes. This ensures targeted and safe stakeholder
engagement worldwide.
“Timely information on KOLs' activities and the latest developments in
their therapeutic area allows medical teams to be more relevant,
valuable partners for KOLs and enables manufacturers to forge
sustainable relationships,” added
Marcus Bergler
, globally recognized
expert in KOL strategy and Veeva’s new European general manager for KOL
Solutions. “We deliver the data, innovative cloud technology, and expert
services medical teams need to create lifelong product advocates.”
Veeva KOL General Manager
Kilian Weiss
will be presenting the new
offering at ExL Pharma's Medical Affairs Strategic Summit East on April
17 and the KOL Engagement and Advisory Board Summit on June 8. For a
more information, please email pr@veeva.com.
Additional Information:
• For more on Veeva KOL Data & Services, please visit: www.veeva.com/KOLdata
•
Stay updated on the latest Veeva news on LinkedIn: www.linkedin.com/company/veeva-systems
•
Follow @veevasystems on Twitter: www.twitter.com/veevasystems
•
Like Veeva on Facebook: www.facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 275 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including statements
regarding benefits from the use of Veeva’s solutions, demand for Veeva’s
solutions, and general business conditions. Any forward-looking
statements contained in this press release are based upon Veeva’s
historical performance and its current plans, estimates, and
expectations and are not a representation that such plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2015, which is available on the
company’s website at www.veeva.com
under the Investors section and on the SEC’s website at www.sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
1 McKinsey & Company, “The secret of successful drug
launches,” by
Hemant Ahlawat
,
Giulia Chierchia
, and
Paul van Arkel
,
March 2014.
Source: Veeva Systems